



#9  
electronic  
**RECEIVED**

JUL 15 2002

TECH CENTER 1600/2900

**CERTIFICATE OF MAILING**  
37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:

July 2, 2002  
Date

Gina N. Shishima

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:  
Ratain et al.

Serial No.: 09/835.082

Filed: April 12, 2001

For: FLAVOPIRIDOL DRUG  
COMBINATIONS AND METHODS  
WITH REDUCED SIDE EFFECTS

Group Art Unit: 1617

Examiner: Jiang, S.

Atty. Dkt. No.: ARCD:374US/GNS

**COPY OF PAPERS  
ORIGINALLY FILED**

**RESPONSE TO RESTRICTION REQUIREMENT DATED JUNE 4, 2002**

Commissioner for Patents  
Washington, D.C. 20231

Commissioner:

This paper is submitted in response to the second Restriction Requirement, dated June 4, 2002, for which the date for response is July 4, 2002.

It is believed that no fee is due; however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to this document, the Commissioner is authorized to deduct said fees from Fulbright & Jaworski L.L.P. Account No.: 50-1212/10103245/GNS.

In response to the restriction requirement which the Examiner imposed, Applicants elect, with traverse, to prosecute the ABC-encoding nucleic acid that encodes ABCG2. Applicants

note that claim 94, reciting "BCRP1," reads on this election because ABCG2 is also known as BCRP1. *See* specification at page 74, line 16.

Applicants traverse this restriction because the ABC transporters have common functional features.

Furthermore, Applicants note that claim 88, from which claim 93 depends, is a linking claim. The MPEP specifically states, "If a linking claim is allowed. . .[the examiner] must examine the claims to the nonelected inventions that are linked to the elected invention by such an allowed linking claim." MPEP §809.04. Thus, Applicants reserve the right to have the other nonelected claims examined should a linking claim be allowed in this case.

The Examiner is invited to contact the undersigned attorney at (512) 536-3081 with any questions, comments or suggestions relating to the referenced patent application.

Respectfully submitted,

Gina N. Shishima  
Reg. No. 45,104  
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.  
600 Congress Avenue, Suite 2400  
Austin, Texas 78701  
(512) 474-5201  
(512) 536-4598 (facsimile)

Date: July 2, 2002



GSHISHIMA@FULBRIGHT.COM  
DIRECT DIAL: (512) 536-3081

## FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP  
600 CONGRESS AVENUE, SUITE 2400  
AUSTIN, TEXAS 78701-3271  
WWW.FULBRIGHT.COM

TELEPHONE: (512) 474-5201  
FACSIMILE: (512) 536-4598

1617  
RECEIVED  
JUL 15 2002  
TECH CENTER 1600/2900

July 2, 2002

### CERTIFICATE OF MAILING 37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:

July 2, 2002  
Date

Gina N. Shishima

Commissioner for Patents  
Washington, D.C. 20231

Re: SN 09/835,082 entitled "FLAVOPIRIDOL DRUG COMBINATIONS AND METHODS WITH REDUCED SIDE EFFECTS" by Ratain *et al.*  
Our ref: ARCD:374US/10103245; Client ref: UCHI:821

Commissioner:

COPY OF PAPERS  
ORIGINALLY FILED

Enclosed for filing in the above-referenced patent application is:

- (1) Response to Restriction Requirement Dated June 4, 2002;
- (2) A return postcard to acknowledge receipt of these materials. Please date stamp and mail this postcard.

Should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to the enclosed materials, the Commissioner is authorized to deduct said fees from Fulbright & Jaworski L.L.P. Account No.: 50-1212/10103245/GNS.

Very truly yours,

Gina N. Shishima  
Reg No. 45,104

GNS/lb  
Enclosures

25184098.1